This economic evaluation found that for remission, both PPOIT and OIT were cost-effective and good value compared with no treatment, with OIT associated with a larger effect size but no clinically meaningful difference. When QALYs are prioritized, PPOIT offers the best value. Key factors associated with cost-effectiveness were treatment product pricing and patient quality of life.
Huang et al. (Fri,) studied this question.